Australia's Sigma Healthcare has walked away from talks to buy the UK drugstore chain Boots. The ASX-listed company decided the acquisition would not satisfy its capital-investment goals or broader strategic objectives. This decision ends preliminary discussions that aimed to leverage a well-known brand for international growth.

Sigma operates the Chemist Warehouse chain and viewed the Boots sale process as a way to speed up its expansion into the United Kingdom. The company sought to use the large footprint and market leadership of the brand to gain an immediate foothold in a competitive European retail environment.

Despite this withdrawal, Sigma says it remains committed to driving growth in its core offshore markets. The company is now refocusing its resources away from this specific UK deal. This move signals a shift in how the firm prioritizes its capital-investment objectives across global operations.